Delving into the Latest Updates on Lutetium (177Lu) edotreotide with Synapse

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals

Synonyms

177Lu-edotreotide, 177Lu-edotreotide PRRT, [177Lu]Lu-DOTATOC

+ [10]

Target

SSTR

Action

antagonists

Mechanism

SSTR antagonists(Somatostatin receptor antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Gastro-Enteropancreatic Neuroendocrine TumorSSTR positive Gastro-Enteropancreatic Neuroendocrine TumorNeuroendocrine neoplasm of lung+ [6]

Inactive Indication-

Originator Organization

Universitätsspital Basel

Active Organization

Grand Pharmaceutical (China) Co., Ltd.Itm Isotope Technologies Munich SEITM Solucin GmbH

+ [1]

Inactive Organization-

License Organization

Grand Pharmaceutical (China) Co., Ltd.

DuChemBIO Co., Ltd.Itm Isotope Technologies Munich SE

+ [1]

Drug Highest PhaseNDA/BLA

First Approval Date-

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Login to view timeline

Structure/Sequence

Molecular FormulaC65H89N14O18S2.Lu

InChIKeyXOPYQJXRGHFPOH-NZMVMCJSSA-K

CAS Registry321835-55-6

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Sequence Code 526980110

Source: *****

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

Start Date27 Oct 2023

Sponsor / Collaborator

Itm Isotope Technologies Munich SE

NCT06045260

/ RecruitingPhase 2

"Receptor Radionuclide Therapy With 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR Positive Patients: a Multicenter, Prospective, Phase II Trial"

Peptide receptor radionuclide therapy (PRRT) may be recommended in G1- G2 GEP-NET patients with disease progression on somatostatine analogues therapy (LUTATHERA®). However, there are several diseases, including neuroendocrine neoplasia not originating from the digestive tract, for which the efficacy of PRRT has already been demonstrated, but which are not currently within the indications of LUTATHERA and therefore cannot benefit from it (i.e. bronchopulmonary, ovarian, renal NETs and neuroendocrine carcinomas). Moreover, the role of PRRT is also accepted in Pheochromocytomas and paragangliomas (PPGLs), Meningiomas, but also as a salvage therapy in pre-treated NET pts, and other SSTR-positive malignancies (Lymphomas, Gliomas...). Least explored among radiopharmaceuticals for SSTR-positive tumors is 177Lu-DOTATOC. This study aims to investigate the efficacy and safety of lutetium (177Lu) edotreotide (Lu-Dotatoc) on all the above-mentioned diseases that could benefit from receptor radionuclide therapy. We believe that this study, which will involve only patients outside the indication of LUTATHERA, will expand the current knowledge of radionuclide receptor therapy with 177Lu- DOTATOC, particularly with regard to objective response and safety parameters, and may consolidate its in the management of these diseases.

Start Date13 Sep 2023

Sponsor / Collaborator-

100 Clinical Results associated with Lutetium (177Lu) edotreotide

Login to view more data

100 Translational Medicine associated with Lutetium (177Lu) edotreotide

Login to view more data

100 Patents (Medical) associated with Lutetium (177Lu) edotreotide

Login to view more data

67

Literatures (Medical) associated with Lutetium (177Lu) edotreotide

01 Mar 2026·JOURNAL OF NUCLEAR MEDICINE

Targeted β ⁻ -Particle Plus Conversion and Auger-Electron Therapy with ¹⁶¹ Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study

Article

Author: McDougall, Lisa ; Müller, Cristina ; Schmid, David E ; Westerbergh, Frida ; Geistlich, Susanne ; van der Meulen, Nicholas P ; Christ, Emanuel ; Bernhardt, Peter ; Nicolas, Guillaume P ; Fani, Melpomeni ; Fricke, Julia G ; Favaretto, Chiara ; Wild, Damian ; Schibli, Roger ; Borgna, Francesca

The goal of this phase 0 study was to determine the absorbed doses in tumors and relevant organs after a test injection of [¹⁶¹Tb]Tb-DOTA-LM3 and [¹⁷⁷Lu]Lu-DOTATOC in the same cohort of patients with grade 1 and 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Methods: In this randomized, crossover, prospective, single-center, open-label phase 0 study, 8 patients received 1 GBq of [¹⁶¹Tb]Tb-DOTA-LM3 and 1 GBq of [¹⁷⁷Lu]Lu-DOTATOC, with a 4-wk interval between injections. Quantitative SPECT/CT imaging was performed 3, 24, 72, and 168 h after administration of each radiopharmaceutical to calculate tumor and organ absorbed doses (3-dimensional dosimetry using a Monte Carlo-based ordered-subset expectation maximization algorithm). Results: After injection of 1 GBq of [¹⁶¹Tb]Tb-DOTA-LM3, SPECT/CT revealed excellent image quality with intense tumor uptake in all patients and a median of the mean effective tumor half-life of 103 h (range, 56-152 h) for [¹⁶¹Tb]Tb-DOTA-LM3 and 83 h (range, 30-122 h) for [¹⁷⁷Lu]Lu-DOTATOC (P = 0.012). The medians of the mean tumor absorbed doses of [¹⁶¹Tb]Tb-DOTA-LM3 and [¹⁷⁷Lu]Lu-DOTATOC were 36.6 Gy/GBq (range, 15-196 Gy/GBq) and 7.0 Gy/GBq (range, 2.4-14.2 Gy/GBq), respectively (P = 0.008). The median kidney and bone marrow absorbed doses were 2.4 Gy/GBq (range, 1.8-3.1 Gy/GBq) and 0.31 Gy/GBq (range, 0.24-0.48 Gy/GBq) for [¹⁶¹Tb]Tb-DOTA-LM3 and 0.6 Gy/GBq (range, 0.4-0.8 Gy/GBq) and 0.04 Gy/GBq (range, 0.03-0.06 Gy/GBq) for [¹⁷⁷Lu]Lu-DOTATOC, respectively (both P = 0.008). According to Common Terminology Criteria for Adverse Events version 5.0, grade 1-3 treatment-emergent adverse events occurred in 6 of 8 patients after administration of 1 GBq of [¹⁶¹Tb]Tb-DOTA-LM3. Conclusion: [¹⁶¹Tb]Tb-DOTA-LM3 showed a 7.6-fold-higher median tumor absorbed dose than that of [¹⁷⁷Lu]Lu-DOTATOC. The tumor-to-bone marrow absorbed dose ratio was in the same range for [¹⁶¹Tb]Tb-DOTA-LM3 as for [¹⁷⁷Lu]Lu-DOTATOC. The administration of 1 GBq of [¹⁶¹Tb]Tb-DOTA-LM3 was safe for all patients, without relevant adverse events.

01 Oct 2025·CLINICAL NUCLEAR MEDICINE

Feasibility of Single Time Point Dosimetry Application in 177Lu-DOTATATE/DOTATOC-treated Pediatric Neuroblastoma

Article

Author: Zheng, Fei ; Liu, Yuxuan ; Yang, Hao ; Li, Pengfei ; Wang, Han ; Sun, Xingyao ; Sun, Xiaorong ; Sun, Yingying

Background::

177Lu-DOTATATE/DOTATOC peptide receptor radionuclide therapy (PRRT) has demonstrated potential for treating pediatric neuroblastoma (NB), and in clinical practice can be measured dosimetry by multi–time point (MTP) dosimetry. However, the high workload and limited patient compliance associated with MTP restrict its application. Consequently, single time point (STP) dosimetry approaches have emerged as a promising alternative, though their effectiveness in pediatric populations has not been thoroughly investigated. This study aimed to assess the dosimetric determination of 177Lu-DOTATATE/DOTATOC in pediatric neuroblastoma patients to determine whether STP could serve as a viable replacement for MTP.

Patients and Methods::

A total of 24 pediatric NB patients who received 1 to 2 cycles of 177Lu-DOTATATE or 177Lu-DOTATOC underwent dosimetric measurement of lesions and critical organs using the 96 hours single time point (STPH) dosimetry method proposed by Hänscheid and colleagues. The results were compared with those obtained from standard MTP.

Results::

In patients treated with 177Lu-DOTATATE, the mean relative deviation absolute values of the STPH-calculated absorbed dose from MTP were <10% for lesions, kidneys, bone marrow, liver, and spleen, with Pearson correlation coefficients of 0.99, 0.93, 0.97, 0.84, and 0.84, respectively. In patients treated with 177Lu-DOTATOC, the mean relative deviation absolute values for kidneys, spleen, and bone marrow were <10%, with Pearson correlation coefficients of 0.97, 0.77, 0.35, 0.48, and 0.93 for lesions, kidneys, bone marrow, liver, and spleen, respectively.

Conclusions::

The findings confirm that the 96 hours STPH method can reliably replace MTP for dosimetric assessment in pediatric NB patients treated with 177Lu-DOTATATE and performed well in renal dosimetry for 177Lu-DOTATOC therapy.

01 Aug 2025·European Journal of Nuclear Medicine and Molecular Imaging

Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors

Article

Author: Wetz, Christoph ; Ruhwedel, Tristan ; Rogasch, Julian ; Steinhagen, Peter ; Galler, Markus ; Amthauer, Holger ; Schatka, Imke

Abstract:

Purpose:

Therapy with [177Lu]Lu-DOTATATE is well established for neuroendocrine tumors (NET), but its production generates [177mLu], raising concerns about waste disposal due to its longer half-life. In contrast, [177mLu] is not formed during [177Lu]Lu-DOTATOC production. However, data on overall survival (OS) and prognostic factors for [177Lu]Lu-DOTATOC remain limited, and its efficacy compared to [177Lu]Lu-DOTATATE is uncertain. This study aimed to analyze OS and radiological response in NET patients treated with [177Lu]Lu-DOTATOC.

Methods:

Monocentric, retrospective analysis of 141 patients with NET (grading: 21% G1, 71% G2, 4% G3, 4% grading unknown; primary: 48% small intestine (SI-NET); 27% pancreas (P-NET); 9% colon/rectum; 1% stomach, 7% lung; 9% CUP-NET) receiving PRRT with [177Lu]Lu-DOTATOC. Cox and logistic regression were used to identify prognostic factors for OS or risk of primary progression.

Results:

Death from any cause was observed in 85 of 141 patients (60.3%). Median OS was 55.2 months (SI NET G1-G2: 62.7 months; P-NET G1-G2: 41.2 months; NET G3: 26.3 months). Multivariable Cox regression identified baseline De Ritis Ratio (p < 0.001), ALP (p < 0.001), CgA (p < 0.001) and prior therapy with mTOR-inhibitors (p = 0.005) as significant prognostic factors of OS. Overall response rate was 12% and disease control rate was 72%. In multivariable logistic regression, primary tumor location (p = 0.04) and CgA (p = 0.01) were significant prognostic factors for higher risk of primary progression.

Conclusion:

The analysis of OS from routine clinical practice shows that PRRT with [177Lu]Lu-DOTATOC is an effective treatment option for NET patients, while generating minimal [177mLu]. The evaluated prognostic factors could help to identify patients who particularly benefit from shorter follow-up intervals.

47

News (Medical) associated with Lutetium (177Lu) edotreotide

12 hours ago

·firstwordpharma.com

FDA rebuffs ITM's radiotherapeutic for neuroendocrine tumours

ITM Isotope Technologies said Monday that the FDA has declined to approve its experimental radiotherapeutic for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).The complete response letter (CRL) for ITM-11 (177Lu-edotreotide) cited chemistry, manufacturing and controls (CMC) issues, as well as items related to inspections of a third-party commercial manufacturing facility. However, the agency didn't identify concerns with the treatment's clinical safety or efficacy, nor did it request additional clinical or nonclinical studies."Our confidence in ITM-11's therapeutic potential has not wavered," said CEO Andrew Cavey. "Our pivotal COMPETE trial data package stands, and our goal remains unchanged as we work toward bringing ITM-11 to patients living with advanced GEP-NETs."According to results from the Phase III trial unveiled last year, the therapy significantly extended progression-free survival (PFS) compared to Novartis' targeted molecular therapy Afinitor (everolimus). COMPETE showed median PFS of 23.9 months with ITM-11 versus 14.1 months with Afinitor, translating to a 33% reduction in the risk of disease progression or death.The trial also set up ITM-11 as a potential challenger to Novartis' radionuclide therapy Lutathera (lutetium Lu 177 dotatate), which is already approved for somatostatin receptor (SSTR)-positive GEP-NETs. In the Phase III NETTER-2 trial, Lutathera demonstrated a PFS benefit of 72% as first-line therapy versus high-dose, long-acting release octreotide alone in patients with SSTR-positive well-differentiated grade 2/3 advanced GEP-NETs. Disease progression or death was delayed by 22.8 months and 8.5 months, respectively, for the two treatments in that study.ITM had been gearing for a potential US launch of ITM-11, securing up to $262.5 million in a debt financing shortly after the COMPETE study read out last year to support commercial readiness for the therapy.Two weeks ago, ITM also announced the creation of Lumara Bio, a dedicated oncology therapeutics division bringing together its early- and late-stage radiopharma pipeline and the internal teams supporting development and commercialisation. The new division was established in part to prepare for ITM-11's market debut. ITM is now reviewing the agency's CRL feedback and determining the steps needed to get ITM-11 back on track.Meanwhile, the radiotherapeutic is also being evaluated in the Phase III COMPOSE study in patients with well-differentiated, aggressive grade 2/3 SSTR-positive GEP-NETs.

Phase 3Clinical ResultOligonucleotidePhase 2

11 Aug 2026

·www.biospace.com

FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues

iStock, sibgat ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns. The FDA has rejected ITM Isotope Technologies’ investigational tumor treatment, citing manufacturing and third-party facility inspection findings. The agency issued a complete response letter (CRL) last week for ITM Isotope’s 177Lu-edotreotide, also known as ITM-11, a radiopharmaceutical designed to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to a Monday company release. The FDA didn’t identify any clinical safety or efficacy issues with the cancer candidate, according to ITM Isotope. ezstandalone.cmd.push(function () { ezstandalone.showAds(129); }); “The CRL stated that the FDA is unable to approve the NDA in its present form and cited CMC- and third-party commercial facility-related items that must be addressed before the application can be approved,” the German biotech said in its release. ITM Isotope is reviewing the feedback to determine next steps but said it plans on resubmitting its new drug application. ITM-11 is a radiopharma therapy that bested Novartis’ mTOR inhibitor everolimus—sold as Afinitor, among other names—in the Phase 3 COMPETE study that evaluated progression-free survival for patients with advanced cancer. “Our confidence in ITM-11’s therapeutic potential has not wavered, and we are committed to working closely with the FDA and our partners to address the items outlined in the CRL,” ITM CEO Andrew Cavey said in a prepared statement. “Our pivotal COMPETE trial data package stands, and our goal remains unchanged as we work toward bringing ITM-11 to patients living with advanced GEP-NETs.” The rejection letter is not yet listed in the FDA’s trove of CRLs. The agency has said it is continuing its “radical transparency” initiative of publishing CRLs soon after they are delivered despite a citizen petition filed earlier this year that questions the legality of the effort. Initially, the FDA had said it would pause the publication of the letters, a statement that was followed by the publication of several CRLs . Insights The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier. April 2, 2026 · 1 min read · Jennifer C. Smith-Parker Read more

Phase 3Oligonucleotide

10 Aug 2026

·www.globenewswire.com

ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11)

No clinical safety or efficacy issues identified and no additional clinical or nonclinical data requestedThe Complete Response Letter for the ongoing ITM-11 New Drug Application (NDA) cites Chemistry, Manufacturing and Controls (CMC) and third-party commercial facility inspection-related items Garching / Munich, Germany and Princeton, New Jersey, August 10, 2026 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 7, 2026, regarding its New Drug Application (NDA) for 177Lu-edotreotide (ITM-11), an investigational agent for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CRL stated that the FDA is unable to approve the NDA in its present form and cited CMC- and third-party commercial facility-related items that must be addressed before the application can be approved. The FDA did not identify any concerns regarding the clinical or nonclinical data package or safety profile of ITM-11. ITM is reviewing the agency’s feedback and assessing the appropriate next steps with the relevant external parties. The Company remains confident in the potential of ITM-11 and is reviewing the FDA’s feedback to determine the most appropriate path forward. The Company intends to resubmit to complete the review of the NDA. “Our confidence in ITM-11’s therapeutic potential has not wavered, and we are committed to working closely with the FDA and our partners to address the items outlined in the CRL,” said Dr. Andrew Cavey, chief executive officer of ITM. “Our pivotal COMPETE trial data package stands, and our goal remains unchanged as we work toward bringing ITM-11 to patients living with advanced GEP-NETs.” About the COMPETE TrialThe COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. It is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians, and our partners through excellence in development, production, and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.comInvestor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.com Attachment ITM Receives Complete Response Letter for ITM-11

Clinical ResultPhase 3OligonucleotideNDA

100 Deals associated with Lutetium (177Lu) edotreotide

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastro-Enteropancreatic Neuroendocrine Tumor	NDA/BLA	United States	Itm Isotope Technologies Munich SE	14 Nov 2025
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 3	China	ITM Solucin GmbH	11 Feb 2025
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 3	China	Grand Pharmaceutical (China) Co., Ltd.	11 Feb 2025
Neuroendocrine neoplasm of lung	Phase 3	Belgium	Itm Isotope Technologies Munich SE	27 Oct 2023
Neuroendocrine neoplasm of lung	Phase 3	France	Itm Isotope Technologies Munich SE	27 Oct 2023
Neuroendocrine neoplasm of lung	Phase 3	Italy	Itm Isotope Technologies Munich SE	27 Oct 2023
Neuroendocrine neoplasm of lung	Phase 3	Spain	Itm Isotope Technologies Munich SE	27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine Tumor	Phase 3	Belgium	Itm Isotope Technologies Munich SE	27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine Tumor	Phase 3	France	Itm Isotope Technologies Munich SE	27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine Tumor	Phase 3	Italy	Itm Isotope Technologies Munich SE	27 Oct 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03049189 (COMPETE, ASCO2026)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	309	177Lu-edotreotide	rtavihekta(gccundxotk) = drctzwaszm tqizttghce (nunvprbucn, -2.7 to 4.4) View more	Positive	29 May 2026
				Everolimus	rtavihekta(gccundxotk) = wzjncepmko tqizttghce (nunvprbucn, -13.9 to -6.0) View more
NCT03049189 (COMPETE, CTgov)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	324	Amino-Acid Solution+177Lu-edotreotide PRRT (177Lu-edotreotide PRRT)	xftfciidff(kiyfomskhr) = qkzkypbkki vwvrnpwiqw (covsvfjztq, owsdriridv - esnfnqjfpq) View more	-	06 Apr 2026
				everolimus (Everolimus)	xftfciidff(kiyfomskhr) = ilcouupyos vwvrnpwiqw (covsvfjztq, xrtmtwgraj - ciewwsqorl) View more
NCT03049189 (COMPETE, Company_Website) Manual	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor Second line \| First line Somatostatin Receptor Positive	309	177Lu-edotreotide	fkultzsepz(ufbctanlsl) = jovrfxvnjz aoxedlgiaz (drxkulduiv ) Met View more	Positive	25 Oct 2025
				Everolimus	fkultzsepz(ufbctanlsl) = nuppxthgdl aoxedlgiaz (drxkulduiv ) Met View more
NCT03049189 (COMPETE, Company_Website \| ESMO2025) Manual	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor Second line \| First line Somatostatin Receptor Positive	309	177Lu-edotreotide	zorzvgvssh(bmkombgsej) = lnbfybxnhl uokwoclgvt (uhvnsjimxg ) View more	Positive	18 Oct 2025
				Everolimus	zorzvgvssh(bmkombgsej) = hzqwjefzro uokwoclgvt (uhvnsjimxg ) View more
NCT03049189 (COMPETE, ESMO2025)	Phase 3	somatostatin receptor positive \| Ki-67 ≤20%	309	177Lu-edotreotide	wbzvownfya(oitweglgqa) = teqoceeznv ldsfgyaeqg (gtbhvhgpuo ) View more	Positive	17 Oct 2025
				Everolimus	wbzvownfya(oitweglgqa) = aqnhtgbyqp ldsfgyaeqg (gtbhvhgpuo ) View more
NCT03049189 (COMPETE, EANM2025 \| GlobeNewswire) Manual	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	309	177Lu-edotreotide (ITM-11)	hbmqepgwjt(adeuvhseyc) = lxoshcelel ifubmfpovj (lgnlhdehyp ) Met View more	Positive	08 Oct 2025
				Everolimus	hbmqepgwjt(adeuvhseyc) = xaqloptqqt ifubmfpovj (lgnlhdehyp ) Met View more
NCT03049189 (COMPETE, Company_Website \| NEWS) Manual	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	309	ITM-11	ftkgnqnned(ipgmdnbnty) = wpxywdkaqn mlvxaapflq (dyqmjdjotl ) Met View more	Positive	28 Jan 2025
				Everolimus	ftkgnqnned(ipgmdnbnty) = hmxycdvkrt mlvxaapflq (dyqmjdjotl ) Met View more
NCT04194125 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	Neuroendocrine Tumors	21	177Lu DOTATOC+ CAPTEM	qnogcahdpa(gccrpjytox) = udbdgmyrtj jhdrefnntz (anrkbxhjwu, 16.0 - NR) View more	Positive	22 Oct 2023
				177Lu DOTATOC+ CAPTEM (panNET)	qnogcahdpa(gccrpjytox) = kcuhiwvamm jhdrefnntz (anrkbxhjwu, 14.0 - NR)
SNMMI2023	Not Applicable	Gastro-Enteropancreatic Neuroendocrine Tumor	-	4 cycles of PRRT	qduoufzxpd(mdqopksihl) = 27 of these 36 patients (75%; 14 SI-NET; 4 CUP-NET; 9 P-NET) experienced PD in iStaging tvurrmtlyp (qlouiiiytt ) View more	-	28 Aug 2023
NCT03049189 (COMPETE, ESMO2018)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	300	Everolimus	yaqoyzjdxc(cmjxavbolq) = ftmohvjujb cfzqmnjorq (vkvwdoeack )	-	21 Oct 2018